

# Kathleen M Giacomini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1457098/publications.pdf>

Version: 2024-02-01

143  
papers

13,085  
citations

38660

50  
h-index

23472

111  
g-index

151  
all docs

151  
docs citations

151  
times ranked

12185  
citing authors

#	ARTICLE	IF	CITATIONS
1	Membrane transporters in drug development. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 215-236.	21.5	2,886
2	Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. <i>Journal of Clinical Investigation</i> , 2007, 117, 1422-1431.	3.9	786
3	SLC transporters as therapeutic targets: emerging opportunities. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 543-560.	21.5	584
4	Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity. <i>Cancer Research</i> , 2006, 66, 8847-8857.	0.4	384
5	Cloning and Functional Expression of a Human Liver Organic Cation Transporter. <i>Molecular Pharmacology</i> , 1997, 51, 913-921.	1.0	374
6	Metformin pathways. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 820-827.	0.7	366
7	The concentrative nucleoside transporter family, SLC28. <i>Pflugers Archiv European Journal of Physiology</i> , 2004, 447, 728-734.	1.3	348
8	Renal Transporters in Drug Development. <i>Annual Review of Pharmacology and Toxicology</i> , 2013, 53, 503-529.	4.2	267
9	Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 5902-5907.	3.3	265
10	Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 5896-5901.	3.3	224
11	<i>cis</i> -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 8902-8907.	3.3	222
12	OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 9983-9988.	3.3	203
13	Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 497-504.	0.7	202
14	Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 890-899.	2.3	185
15	Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 395-405.	5.7	183
16	Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 687-699.	0.7	175
17	Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 5480-5485.	3.3	173
18	Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 531-539.	1.9	172

#	ARTICLE	IF	CITATIONS
19	Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. <i>Nature Genetics</i> , 2016, 48, 1055-1059.	9.4	165
20	Profiling of a Prescription Drug Library for Potential Renal Drug-Drug Interactions Mediated by the Organic Cation Transporter 2. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 4548-4558.	2.9	141
21	Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 836-864.	2.3	141
22	Discovery of Potent, Selective Multidrug and Toxin Extrusion Transporter 1 (MATE1, SLC47A1) Inhibitors Through Prescription Drug Profiling and Computational Modeling. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 781-795.	2.9	131
23	Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 15810-15815.	3.3	120
24	The Clinical Pharmacogenetics Implementation Consortium Guideline for <i>SLCO1B1</i> , <i>ABCG2</i> , and <i>CYP2C9</i> genotypes and Statin-Associated Musculoskeletal Symptoms. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1007-1021.	2.3	120
25	Metformin Pharmacogenomics: Current Status and Future Directions. <i>Diabetes</i> , 2014, 63, 2590-2599.	0.3	112
26	Transporters Involved in Metformin Pharmacokinetics and Treatment Response. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2245-2250.	1.6	108
27	A genome-wide association study of bronchodilator response in Latinos implicates rare variants. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 370-378.e15.	1.5	105
28	Organic Anion Transporter 2 ( <i>SLC22A7</i> ) Is a Facilitative Transporter of cGMP. <i>Molecular Pharmacology</i> , 2008, 73, 1151-1158.	1.0	103
29	Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 803-817.	2.3	99
30	Transport of Paraquat by Human Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Family. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 695-700.	1.3	98
31	Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. <i>Pharmacogenomics Journal</i> , 2009, 9, 127-136.	0.9	94
32	Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). <i>Pharmacogenetics and Genomics</i> , 2005, 15, 201-209.	0.7	93
33	Targeted Disruption of Organic Cation Transporter 3 Attenuates the Pharmacologic Response to Metformin. <i>Molecular Pharmacology</i> , 2015, 88, 75-83.	1.0	88
34	The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, F905-F912.	1.3	87
35	Molecular Modeling and Ligand Docking for Solute Carrier (SLC) Transporters. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 843-856.	1.0	85
36	Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 70-70.	21.5	80

#	ARTICLE	IF	CITATIONS
37	Towards Quantitation of the Effects of Renal Impairment and Probenecid Inhibition on Kidney Uptake and Efflux Transporters, Using Physiologically Based Pharmacokinetic Modelling and Simulations. <i>Clinical Pharmacokinetics</i> , 2014, 53, 283-293.	1.6	79
38	Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3). <i>Molecular Pharmaceutics</i> , 2015, 12, 4301-4310.	2.3	79
39	Identification and Quantitative Assessment of Uremic Solutes as Inhibitors of Renal Organic Anion Transporters, OAT1 and OAT3. <i>Molecular Pharmaceutics</i> , 2016, 13, 3130-3140.	2.3	79
40	Organic Cation Transporters Modulate the Uptake and Cytotoxicity of Picoplatin, a Third-Generation Platinum Analogue. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1058-1069.	1.9	74
41	Arginine 454 and Lysine 370 Are Essential for the Anion Specificity of the Organic Anion Transporter, rOAT3. <i>Biochemistry</i> , 2001, 40, 5511-5520.	1.2	70
42	A Comprehensive Analysis of Ontogeny of Renal Drug Transporters: mRNA Analyses, Quantitative Proteomics, and Localization. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1083-1092.	2.3	69
43	Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 27, 665-670.	2.3	62
44	Interaction of nucleoside analogues with the sodium-nucleoside transport system in brush border membrane vesicles from human kidney. <i>Pharmaceutical Research</i> , 1993, 10, 423-426.	1.7	61
45	The activities of drug inactive ingredients on biological targets. <i>Science</i> , 2020, 369, 403-413.	6.0	61
46	Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1); Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.9	58
47	Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 770-780.	0.7	56
48	Functional Genetic Diversity in the High-Affinity Carnitine Transporter OCTN2 (SLC22A5). <i>Molecular Pharmacology</i> , 2006, 70, 1602-1611.	1.0	55
49	LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5000-5006.	1.0	54
50	Rapid Method To Determine Intracellular Drug Concentrations in Cellular Uptake Assays: Application to Metformin in Organic Cation Transporter 1-Transfected Human Embryonic Kidney 293 Cells. <i>Drug Metabolism and Disposition</i> , 2016, 44, 356-364.	1.7	54
51	Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1). <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7358-7373.	2.9	54
52	LAT-1 activity of meta-substituted phenylalanine and tyrosine analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2616-2621.	1.0	53
53	Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers. <i>Clinical and Translational Science</i> , 2019, 12, 388-399.	1.5	53
54	Molecular Determinants of Substrate Selectivity in Na <sup>+</sup> -dependent Nucleoside Transporters. <i>Journal of Biological Chemistry</i> , 1997, 272, 28845-28848.	1.6	51

#	ARTICLE	IF	CITATIONS
55	Gene Expression Profiling of Transporters in the Solute Carrier and ATP-Binding Cassette Superfamilies in Human Eye Substructures. <i>Molecular Pharmaceutics</i> , 2013, 10, 650-663.	2.3	50
56	The effect of probenecid on the renal elimination of cimetidine. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 45, 444-452.	2.3	49
57	Pharmacogenomics and Patient Care: One Size Does Not Fit All. <i>Science Translational Medicine</i> , 2012, 4, 153ps18.	5.8	49
58	High Selectivity of the $\hat{1}^3$ -Aminobutyric Acid Transporter 2 (GAT-2, SLC6A13) Revealed by Structure-based Approach. <i>Journal of Biological Chemistry</i> , 2012, 287, 37745-37756.	1.6	49
59	The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 408-419.	2.3	48
60	Reduced Renal Clearance of Cefotaxime in Asians with a Low-Frequency Polymorphism of OAT3 (SLC22A8). <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3451-3457.	1.6	47
61	The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. <i>Clinical Pharmacokinetics</i> , 2016, 55, 711-721.	1.6	47
62	The role of ATM in response to metformin treatment and activation of AMPK. <i>Nature Genetics</i> , 2012, 44, 359-360.	9.4	46
63	Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content. <i>PLoS Biology</i> , 2018, 16, e2002907.	2.6	45
64	Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). <i>Pharmacogenetics and Genomics</i> , 2007, 17, 773-782.	0.7	43
65	The pharmacokinetics of the enantiomers of atenolol. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 45, 403-410.	2.3	42
66	Role of Organic Cation Transporter 1, OCT1 in the Pharmacokinetics and Toxicity of cis-Diammine(pyridine)chloroplatinum(II) and Oxaliplatin in Mice. <i>Pharmaceutical Research</i> , 2011, 28, 610-625.	1.7	42
67	Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 57-61.	2.3	42
68	Organic cation transporter 3 (Oct3) is a distinct catecholamines clearance route in adipocytes mediating the beiging of white adipose tissue. <i>PLoS Biology</i> , 2019, 17, e2006571.	2.6	41
69	Genomic Characterization of Metformin Hepatic Response. <i>PLoS Genetics</i> , 2016, 12, e1006449.	1.5	41
70	Molecular Mechanisms for Species Differences in Organic Anion Transporter 1, OAT1: Implications for Renal Drug Toxicity. <i>Molecular Pharmacology</i> , 2018, 94, 689-699.	1.0	40
71	Opportunities and challenges for the computational interpretation of rare variation in clinically important genes. <i>American Journal of Human Genetics</i> , 2021, 108, 535-548.	2.6	40
72	Emerging Clinical Importance of Hepatic Organic Cation Transporter 1 (OCT1) in Drug Pharmacokinetics, Dynamics, Pharmacogenetic Variability, and Drug Interactions. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 758-760.	2.3	39

#	ARTICLE	IF	CITATIONS
73	A conserved role of the insulin-like signaling pathway in diet-dependent uric acid pathologies in <i>Drosophila melanogaster</i> . <i>PLoS Genetics</i> , 2019, 15, e1008318.	1.5	39
74	Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 16009-16018.	3.3	39
75	Prediction and validation of enzyme and transporter off-targets for metformin. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 463-475.	0.8	37
76	A research roadmap for next-generation sequencing informatics. <i>Science Translational Medicine</i> , 2016, 8, 335ps10.	5.8	37
77	Genome-Wide Discovery of Drug-Dependent Human Liver Regulatory Elements. <i>PLoS Genetics</i> , 2014, 10, e1004648.	1.5	36
78	A New Era in Pharmacovigilance: Toward Real-World Data and Digital Monitoring. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1197-1202.	2.3	36
79	Genetic Variation in the Proximal Promoter of ABC and SLC Superfamilies: Liver and Kidney Specific Expression and Promoter Activity Predict Variation. <i>PLoS ONE</i> , 2009, 4, e6942.	1.1	34
80	Genetic Variants in <i>CPA6</i> and <i>PRPF31</i> Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1428-1440.	0.3	32
81	Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 28, 417-424.	2.3	31
82	Effect of hemodialysis on propoxyphene and norpropoxyphene concentrations in blood of anephric patients*. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 27, 508-514.	2.3	31
83	Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans. <i>Frontiers in Pharmacology</i> , 2016, 7, 135.	1.6	28
84	ITC Commentary on Metformin Clinical Drug-Drug Interaction Study Design That Enables an Efficacy- and Safety-Based Dose Adjustment Decision. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 781-784.	2.3	28
85	A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 82-92.	0.7	27
86	The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers. <i>Clinical Pharmacokinetics</i> , 2016, 55, 495-506.	1.6	27
87	Emerging Roles of the Human Solute Carrier 22 Family. <i>Drug Metabolism and Disposition</i> , 2022, 50, 1193-1210.	1.7	26
88	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 420-427.	0.7	25
89	Reverse Translational Research of <i>ABCG2</i> (BCRP) in Human Disease and Drug Response. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 233-242.	2.3	25
90	GenEpi: gene-based epistasis discovery using machine learning. <i>BMC Bioinformatics</i> , 2020, 21, 68.	1.2	25

#	ARTICLE	IF	CITATIONS
91	Drug-nutrient interactions: discovering prescription drug inhibitors of the thiamine transporter ThTR-2 (SLC19A3). <i>American Journal of Clinical Nutrition</i> , 2020, 111, 110-121.	2.2	24
92	The Effect of Uremic Solutes on the Organic Cation Transporter 2. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2551-2557.	1.6	23
93	Computational Discovery and Experimental Validation of Inhibitors of the Human Intestinal Transporter OATP2B1. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 1402-1413.	2.5	23
94	Unraveling the functional role of the orphan solute carrier, SLC22A24 in the transport of steroid conjugates through metabolomic and genome-wide association studies. <i>PLoS Genetics</i> , 2019, 15, e1008208.	1.5	23
95	Genome-Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 623-631.	2.3	23
96	Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. <i>Diabetes Care</i> , 2021, 44, 2673-2682.	4.3	23
97	Genetic variants of human organic anion transporter 4 demonstrate altered transport of endogenous substrates. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, F767-F775.	1.3	22
98	Genetic variation in human aquaporins and effects on phenotypes of water homeostasis. <i>Human Mutation</i> , 2008, 29, 1108-1117.	1.1	21
99	Deorphaning a solute carrier 22 family member, SLC22A15, through functional genomic studies. <i>FASEB Journal</i> , 2020, 34, 15734-15752.	0.2	21
100	Stereoselective interactions of organic cations with the organic cation transporter in OK cells. <i>Pharmaceutical Research</i> , 1993, 10, 1169-1173.	1.7	20
101	Effect of Concentration-Dependent Binding to Plasma Proteins on the Pharmacokinetics and Pharmacodynamics of Disopyramide. <i>Clinical Pharmacokinetics</i> , 1984, 9, 42-48.	1.6	16
102	Sorting of rat SPNT in renal epithelium is independent of N-glycosylation. <i>Pharmaceutical Research</i> , 2003, 20, 319-323.	1.7	16
103	Interactions of Oral Molecular Excipients with Breast Cancer Resistance Protein, BCRP. <i>Molecular Pharmaceutics</i> , 2020, 17, 748-756.	2.3	16
104	Drugs in COVID-19 Clinical Trials: Predicting Transporter-Mediated Drug-Drug Interactions Using In Vitro Assays and Real-World Data. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 108-122.	2.3	16
105	New and Emerging Research on Solute Carrier and ATP Binding Cassette Transporters in Drug Discovery and Development: Outlook From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 540-561.	2.3	16
106	Correction for Volume Shift during Equilibrium Dialysis by Measurement of Protein Concentration. <i>Pharmaceutical Research</i> , 1984, 01, 179-181.	1.7	15
107	Unmet needs: Research helps regulators do their jobs. <i>Science Translational Medicine</i> , 2015, 7, 315ps22.	5.8	15
108	OCT1 in hepatic steatosis and thiamine disposition. <i>Cell Cycle</i> , 2015, 14, 283-284.	1.3	15

#	ARTICLE	IF	CITATIONS
109	Human Concentrative Nucleoside Transporter 3 (hCNT3, SLC28A3) Forms a Cyclic Homotrimer. <i>Biochemistry</i> , 2017, 56, 3475-3483.	1.2	15
110	Taurine transport in cultured choroid plexus. <i>Pharmaceutical Research</i> , 1997, 14, 406-409.	1.7	14
111	Drug Metabolites Potently Inhibit Renal Organic Anion Transporters, OAT1 and OAT3. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 347-353.	1.6	14
112	l-Type amino acid transporter 1 activity of 1,2,3-triazolyl analogs of l-histidine and l-tryptophan. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 2254-2258.	1.0	13
113	Functional and structural analysis of rare SLC2A2 variants associated with Fanconiâ€Bickel syndrome and metabolic traits. <i>Human Mutation</i> , 2019, 40, 983-995.	1.1	13
114	High Throughput Screening of a Prescription Drug Library for Inhibitors of Organic Cation Transporter 3, OCT3. <i>Pharmaceutical Research</i> , 2022, 39, 1599-1613.	1.7	13
115	Expression of a renal Na <sup>+</sup> -nucleoside cotransport system (N2) in <i>Xenopus laevis</i> oocytes. <i>Pflugers Archiv European Journal of Physiology</i> , 1994, 427, 381-383.	1.3	12
116	Pharmacogenetics of Antidiabetic Drugs. <i>Advances in Pharmacology</i> , 2018, 83, 361-389.	1.2	12
117	Formycin B elimination from the cerebrospinal fluid of the rat. <i>Pharmaceutical Research</i> , 1993, 10, 611-615.	1.7	11
118	Impact of Pharmaceutical Excipients on Oral Drug Absorption: A Focus on Intestinal Drug Transporters. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 323-325.	2.3	10
119	Clinical Pharmacology & Therapeutics 2030. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 13-16.	2.3	8
120	Scientific considerations for global drug development. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	8
121	Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics. <i>Clinical and Translational Science</i> , 2021, 14, 1431-1443.	1.5	8
122	Renal transport of drugs: an overview of methodology with application to cimetidine. <i>Pharmaceutical Research</i> , 1988, 05, 465-471.	1.7	7
123	Stereoselective binding of disopyramide to plasma proteins. <i>Pharmaceutical Research</i> , 1988, 05, 316-318.	1.7	7
124	Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins. <i>British Journal of Pharmacology</i> , 2021, 178, 1459-1474.	2.7	7
125	Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein. <i>AAPS Journal</i> , 2021, 23, 106.	2.2	7
126	Research Projects Supported by the <sc>University of California, San Francisco</sc>â€Stanford Center of Excellence in Regulatory Science and Innovation. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 815-818.	2.3	6



#	ARTICLE	IF	CITATIONS
127	Expanding Precompetitive Multisector Collaborations to Advance Drug Development and Pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 96-101.	2.3	6
128	Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 559-562.	2.3	6
129	Effect of Probenecid on the Pharmacokinetics and Pharmacodynamics of Procainamide. <i>Journal of Clinical Pharmacology</i> , 1991, 31, 429-432.	1.0	5
130	Mechanisms of 5-fluorouracil (5-FU) transport in isolated rabbit choroid plexus tissue slices. <i>Pharmaceutical Research</i> , 1996, 13, 1276-1278.	1.7	5
131	Neural production of kynurenic acid in <i>Caenorhabditis elegans</i> requires the AAT-1 transporter. <i>Genes and Development</i> , 2020, 34, 1033-1038.	2.7	5
132	A Critical Overview of the Biological Effects of Excipients (Part I): Impact on Gastrointestinal Absorption. <i>AAPS Journal</i> , 2022, 24, 60.	2.2	5
133	Cimetidine elimination from the cerebrospinal fluid of the rat. <i>Pharmaceutical Research</i> , 1988, 05, 628-633.	1.7	3
134	The Effects of Genetic Mutations and Drugs on the Activity of the Thiamine Transporter, SLC19A2. <i>AAPS Journal</i> , 2021, 23, 35.	2.2	2
135	In Vitro Evaluation of Excipients as Inhibitors of Human Intestinal P-glycoprotein. <i>FASEB Journal</i> , 2019, 33, 814.3.	0.2	2
136	Novel Technologies Enable Mechanistic Understanding and Modeling of Drug Exposure and Response. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1045-1047.	2.3	1
137	A Tribute to Professor Per Artursson - Scientist, Explorer, Mentor, Innovator, and Giant in Pharmaceutical Research. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 2-11.	1.6	1
138	Pharmacogenomic mechanisms of drug toxicity. , 2022, , 303-322.		1
139	Mechanisms and genetics of drug transport. , 2022, , 213-239.		1
140	Verapamil interacts stereoselectively with the muscarinic receptor. <i>Pharmaceutical Research</i> , 1985, 02, 94-95.	1.7	0
141	SLCO1B1 Variation and Methotrexate Disposition in Children with Acute Lymphoblastic Leukemia: The Importance of Rare Variants in Pharmacogenetics. <i>Blood</i> , 2011, 118, 571-571.	0.6	0
142	Germline Genetic Polymorphisms Are Associated with Disease-Free Survival in Adults with Acute Myeloid Leukemia (AML): A Genomewide Association Study From the Pgrn-Riken Global Alliance.. <i>Blood</i> , 2012, 120, 2548-2548.	0.6	0
143	Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. <i>Diabetes Care</i> 2021;44:2673-2682. <i>Diabetes Care</i> , 2022, 45, e82-e83.	4.3	0